Navigation Links
Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid

BRIDGEWATER, N.J., May 03, 2007 /PRNewswire-FirstCall/ -- Alpharma Inc. , a leading global specialty pharmaceutical company through its Pharmaceuticals Division, this week presented positive results of a pharmacokinetic study of its investigational abuse-deterrent, extended-release opioid at the 26th annual scientific meeting of the American Pain Society in Washington, D.C. The data demonstrated the release characteristics of this extended-release morphine sulfate plus sequestered naltrexone product were similar to that found in previous studies of Alpharma's currently marketed KADIAN(R) (morphine sulfate extended-release) Capsules.

"There is a clear need for new medications that provide pain relief while deterring abuse and we believe our technology may offer a significant abuse- deterrent option for physicians treating patients suffering from moderate-to- severe chronic pain," says Joseph Stauffer, DO, Chief Medical Officer Clinical Research & Medical Affairs and Senior Vice President, Alpharma Pharmaceuticals LLC. "We are committed to offering physicians the tools needed to treat patients with moderate-to-severe chronic pain."

Alpharma's proprietary technology combines an extended-release opioid with a sequestered core of the antagonist, naltrexone. If the product is taken as directed, it is intended that the naltrexone will remain sequestered and the patient will achieve pain relief similar to KADIAN(R) (morphine sulfate extended-release) Capsules. If the capsule is tampered with by crushing, chewing or dissolving, it is designed so that the naltrexone will be released and euphoria will be abated.

Study Design and Results

In the single-dose, open-label, two-period crossover study (fasted and fed) in eight healthy subjects, 21 to 45 years of age, after an overnight fast, subjects either received the study drug (containing 60 mg morphine sulfate) or consumed a standard high-cal
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:8/1/2014)... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... results for the second quarter ended June 30, ... see encouraging advancements in the US commercialization of ... total prescriptions and estimated total per week prescriptions ... President and Chief Executive Officer. "Other recent notable ...
(Date:8/1/2014)... , Aug. 1, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com ... China Potassium Nitrate Industry" and "2014 Deep Research ... Industry" reports to its research database. ... 2014 Deep Research Report on Global and ... in-depth research report on China ...
(Date:7/31/2014)... 2014 Cipla Europe ... bekannt, vor kurzem für OneDose ReadyfusOR™ von ... chirurgischen Eingriffen eine kommerzielle Zusammenarbeit begonnen zu ... und weiterer europäischer Länder abdeckt. Cipla plant, ... gefüllte OneDose ReadyfusOR später in diesem Jahr ...
Breaking Medicine Technology:Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3
... Ohio, Jan. 10, 2012   Bedford Laboratories™ today issued updated ... on August 2, 2011: , Polymyxin B for ... 1942980 – Exp. Date August 2013 and Lot 1895027 – ... 10 mg per vial – NDC #55390-037-10 Lot 1865067 – ...
... a dynamic, service-oriented healthcare technology company has announced an ... and Practice Management software products. This update will enable ... the requirements set forth by the Centers for Medicare ... (Logo: http://photos.prnewswire.com/prnh/20101115/NY01712LOGO ) Currently, SequelMed ...
Cached Medicine Technology:Bedford Laboratories™ Issues Guidance on 2011 Voluntary Recall of Polymyxin B for Injection USP and Vecuronium Bromide for Injection Related to Glass Particulates 2Bedford Laboratories™ Issues Guidance on 2011 Voluntary Recall of Polymyxin B for Injection USP and Vecuronium Bromide for Injection Related to Glass Particulates 3SequelMed Announces ANSI 5010 Upgrade for Its Users 2
(Date:8/1/2014)... August 01, 2014 For the first ... Organic Cotton Farm & Fiber Report and the Organic ... the entire organic cotton supply chain resulting in the ... the organization’s Managing Director, reports, “We are looking holistically ... are the beginning of a long value chain and ...
(Date:8/1/2014)... 01, 2014 In the 18th and ... was fundamental to the practice of medicine. Today, according ... Kleyne, water therapy has been relegated to a minor ... change, water shortages, drought and pollution are creating a ... Kleyne Hour Power of Water host contends that hydrotherapy’s ...
(Date:8/1/2014)... Lake City, UT (PRWEB) August 01, 2014 ... Medical Billing Experts, LLC (MBX) with the convergence ... Medical Professionals (BOSS), Salt Lake City, UT; Premier ... Six Seven Group (67G) of Charlotte, NC. Together ... some of the nation’s largest radiology group practices, ...
(Date:8/1/2014)... Angeles, CA (PRWEB) August 01, 2014 Did ... The goal of Sarcoma Awareness Month is to raise awareness ... of, and treatment options for, sarcoma. According to the American ... the disease in 2014, while 12,000 new soft tissue sarcomas ... as familiar with sarcoma tumors as they are other kinds ...
(Date:8/1/2014)... NV (PRWEB) August 01, 2014 Fresh from ... a look at some new and exciting products. With the ... to gear up with some exciting new products. There have ... which is mentioned below, but other brands like Cozzia and ... new chairs. The Las Vegas Market takes place two times ...
Breaking Medicine News(10 mins):Health News:Surveys Reveal the Top 10 Organic Cotton Users and the Top 10 Producing Countries 2Health News:Water Researcher Advocates Reevaluation of 18th and 19th Century Water Therapy Movement 2Health News:Water Researcher Advocates Reevaluation of 18th and 19th Century Water Therapy Movement 3Health News:Three Market Leaders Come Together As One To Form A New Breed of Medical Billing Companies 2Health News:Three Market Leaders Come Together As One To Form A New Breed of Medical Billing Companies 3Health News:July Was Sarcoma Awareness Month! 2Health News:July Was Sarcoma Awareness Month! 3Health News:July Was Sarcoma Awareness Month! 4Health News:A Recap of the 2014 Summer Las Vegas Furniture Market by Emassagechair.com 2Health News:A Recap of the 2014 Summer Las Vegas Furniture Market by Emassagechair.com 3
... acquire greater solemnity and respectability about it. For a British ... of the movement of the elderly with dementia. ... for keeping track of people afflicted with dementia. They could ... ,In electronic tagging the tag is usually a wristband. ...
... chronically exposed to family turmoil, violence, noise, poor housing ... strain// than other young people. ,However, when ... these negative physiological changes, reports a new study from ... that the cardiovascular systems of youths who are exposed ...
... days has an increased chance of getting heart disease ... Association's 8th Annual Conference on Arteriosclerosis. ... group of college students who drank heavily had higher ... inflammation that can increase the risk for heart disease. ...
... the carotid artery by dental x-rays is not enough evidence ... a review published in the Journal of the American Dental ... leading causes of death and disability among adults in the ... and nutrients to the brain bursts or becomes clogged by ...
... Alzheimer's disease experience brain structure changes years before any ... Researchers say these findings// may help identify people at ... to Alzheimer's disease. ,Researchers performed brain scans ... of 65 who were considered cognitively normal at the ...
... call to the Global Fund to Fight AIDS, TB, and ... or else risk a situation in which medicines// for these ... are no health professionals to deliver them. ,"Recent ... Ooms (Medecins Sans Fronti?¨res, Belgium) and colleagues, "suggest an intention ...
Cached Medicine News:Health News:Electronic Tagging - for the Elderly Now! 2Health News:Adolescents Exposed to Family Turmoil and Violence Face Stress-related Problems 2Health News:Alcohol Abuse During College Days Leads to Heart Disease in Later Life 2Health News:Alcohol Abuse During College Days Leads to Heart Disease in Later Life 3Health News:Dental X-rays of Carotid Artery Cannot Estimate Stroke Risk 2Health News:Brain Structure Changes Years Before Memory Loss Begins 2Health News:Health Expert’s Appeal to Global Fund to Fight HIV, TB and Malari 2
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
... Since 1991 Intersurgical Incorporated ... filters, heat and moisture ... therapy products, hand-held nebulizers ... of accessories and connectors ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
... The Ulti-Mist™ HME product line has ... from pediatrics to adults and from intubated ... offer superior humidification for both anesthesia and ... and HME/Filters provide maximum protection for patients ...
Medicine Products: